On May 20, 2021 AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") reported that Phase 1 testing data will be presented at the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting June 4, 2021 (Press release, AIkido Pharma, MAY 20, 2021, View Source [SID1234580404]). The presentation of the data will be by Dr. Scott Tagawa, a Professor of Medicine & Urology at Weill Cornell Medicine and an AIkido Pharma Scientific Advisory Board member.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ASCO Presentation Details:

Title: "Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC)"
Tract: Genitourinary Cancer—Prostate, Testicular, and Penile
Presenter: Dr. Scott Tagawa MD, MS, FACP
Abstract Number: 5015
Date and Time: Available Starting June 4, 2021, 9:00 am (EST)

The Abstract from this study has been released on the ASCO (Free ASCO Whitepaper) Annual Meeting website (View Source), a portion of which states: "PSMA-targeted alpha-emitter 225Ac utilizing intact antibody J591 is tolerable with early evidence of clinical activity. Based upon these results, a follow up study [NCT04506567] testing multiple and fractionated dosing of 225Ac-J591 is underway. Clinical trial information: NCT03276572 (View Source )

The full ASCO (Free ASCO Whitepaper) meeting program is available at: www.asco.org